Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.

PI: Dr. Eric Knoche

Study Coordinator: Linda Schimmoeller

This study has just been fully approved and will now begin to enroll patients.

To learn more about MVP and how you can join contact our research office at (314) 289-7690